The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for treating complicated urinary tract infections (cUTIs) in adults with limited oral treatment options. This approval is based on the PIVOT-PO phase III trial showing Utebzi's effectiveness comparable to intravenous treatment. Utebzi offers a convenient oral alternative to IV carbapenems, potentially reducing hospital stays and healthcare costs. It is expected to be available in the US by the end of 2026, providing a new option against resistant infections affecting over 3 million Americans annually.
The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
Biotech companies are increasingly adopting a dual-track approach by preparing for IPOs while also engaging with potential acquirers, as investors have become more selective since the pandemic boom. Big Pharma is actively seeking to replenish drug pi...
